Literature DB >> 27284349

ROCK2 mediates the proliferation of pulmonary arterial endothelial cells induced by hypoxia in the development of pulmonary arterial hypertension.

Feng Qiao1, Zhitian Zou1, Chunhui Liu1, Xiaofeng Zhu1, Xiaoqiang Wang1, Chengpeng Yang1, Tengjiao Jiang1, Ying Chen2.   

Abstract

It has been reported that RhoA activation and Rho-kinase (ROCK) expression are increased in chronic hypoxic lungs, and the long-term inhibition of ROCK markedly improves the survival of patients with pulmonary arterial hypertension (PAH). However, whether Rho-kinase α (ROCK2) participates in regulation of the growth of pulmonary arterial endothelial cells (PAECs) remains unknown. The aim of the present study was to investigate the effect of hypoxia on the proliferation of PAECs and the role of ROCK2 in the underlying mechanism. The results of western blotting and reverse transcription-quantitative polymerase chain reaction analysis showed that hypoxia increased the activity and expression of ROCK2 in PAECs, and the stimulating effects of hypoxia on the proliferation of PAECs were attenuated by either the ROCK inhibitor Y27632 or transfection with ROCK2 small interfering RNA. Moreover, analysis of cyclin A and cyclin D1 mRNA expression indicated that ROCK2 mediates the cell cycle progression promoted by hypoxia. These results indicate that hypoxia promotes the proliferation of pulmonary arterial endothelial cells via activation of the ROCK2 signaling pathway.

Entities:  

Keywords:  ROCK2; hypoxia; proliferation; pulmonary arterial endothelial cells; pulmonary arterial hypertension

Year:  2016        PMID: 27284349      PMCID: PMC4887771          DOI: 10.3892/etm.2016.3214

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  20 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

3.  ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice.

Authors:  O Nakagawa; K Fujisawa; T Ishizaki; Y Saito; K Nakao; S Narumiya
Journal:  FEBS Lett       Date:  1996-08-26       Impact factor: 4.124

Review 4.  Recent progress in the management of pulmonary hypertension.

Authors:  Yoshihiro Fukumoto; Hiroaki Shimokawa
Journal:  Circ J       Date:  2011-07-11       Impact factor: 2.993

5.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

6.  Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension.

Authors:  Zhulanqiqige Do e; Yoshihiro Fukumoto; Aya Takaki; Shunsuke Tawara; Junko Ohashi; Makoto Nakano; Tomohiro Tada; Kenya Saji; Kohichiro Sugimura; Hiroshi Fujita; Yasushi Hoshikawa; Jun Nawata; Takashi Kondo; Hiroaki Shimokawa
Journal:  Circ J       Date:  2009-07-09       Impact factor: 2.993

7.  Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death.

Authors:  Dean Thumkeo; Jeongsin Keel; Toshimasa Ishizaki; Masaya Hirose; Kimiko Nonomura; Hiroko Oshima; Masanobu Oshima; Makoto M Taketo; Shuh Narumiya
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

8.  20-HETE increases superoxide production and activates NAPDH oxidase in pulmonary artery endothelial cells.

Authors:  Meetha Medhora; Yuenmu Chen; Stephanie Gruenloh; Daniel Harland; Sreedhar Bodiga; Jacek Zielonka; Debebe Gebremedhin; Ying Gao; John R Falck; Siddam Anjaiah; Elizabeth R Jacobs
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-02-22       Impact factor: 5.464

Review 9.  Development of Rho-kinase inhibitors for cardiovascular medicine.

Authors:  Hiroaki Shimokawa; Mamunur Rashid
Journal:  Trends Pharmacol Sci       Date:  2007-05-07       Impact factor: 14.819

Review 10.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  6 in total

Review 1.  Rho-Associated Coiled-Coil Kinase (ROCK) in Molecular Regulation of Angiogenesis.

Authors:  Jing Liu; Youichiro Wada; Mari Katsura; Hideto Tozawa; Nicholas Erwin; Carolyn M Kapron; Gang Bao; Ju Liu
Journal:  Theranostics       Date:  2018-11-26       Impact factor: 11.556

2.  The level of ROCK1 and ROCK2 in patients with pulmonary hypertension in plateau area.

Authors:  Bing Liu; Rong Chang; Zhili Duan; Xiaofei Zhang; Yusong Shen; Xiangbo Liu; Jinchun Wu; Yajun Tuo; Junming Luo
Journal:  Sci Rep       Date:  2018-06-19       Impact factor: 4.379

3.  Identification of autophagy-related biomarkers in patients with pulmonary arterial hypertension based on bioinformatics analysis.

Authors:  Zhisong Yang; Li Zhou; Haiyan Ge; Weimin Shen; Lin Shan
Journal:  Open Med (Wars)       Date:  2022-07-06

4.  Alternative splicing signature of alveolar type II epithelial cells of Tibetan pigs under hypoxia-induced.

Authors:  Haonan Yuan; Xuanbo Liu; Zhengwen Wang; Yue Ren; Yongqing Li; Caixia Gao; Ting Jiao; Yuan Cai; Yanan Yang; Shengguo Zhao
Journal:  Front Vet Sci       Date:  2022-09-16

Review 5.  ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension.

Authors:  Tadeu L Montagnoli; Jaqueline S da Silva; Susumu Z Sudo; Aimeé D Santos; Gabriel F Gomide; Mauro P L de Sá; Gisele Zapata-Sudo
Journal:  Cells       Date:  2021-06-30       Impact factor: 7.666

6.  LncRNA PAXIP1-AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1/WIPF1/RhoA axis.

Authors:  Rong Song; Si Lei; Song Yang; Shang-Jie Wu
Journal:  J Cell Mol Med       Date:  2021-07-10       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.